Semaglutide
BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity
Novo Nordisk · Phase 3 · Not yet recruiting · Enrollment 352
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Group A: Bofanglutida (GZR18), | n/r | n/r | n/r | n/r | n/r |
| Group B: Semaglutide | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.